Clinical Cancer Research, Vol 4, Issue 2 455-462, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts

WC Zamboni, PJ Houghton, J Thompson, PJ Cheshire, SK Hanna, LB Richmond, X Lou and CF Stewart
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

The antitumor activity of irinotecan in vitro primarily results from its hydrolysis by carboxylesterase to the active metabolite SN-38. The present study was conducted to evaluate the effect of human neuroblastoma xenografts on irinotecan and SN-38 disposition after i.v. and oral irinotecan administration. Non-tumor-bearing mice and mice bearing three different human neuroblastoma xenograft lines (NB1691, NB1643, and NBEB) were given irinotecan (10 mg/kg) by short i.v. injection into the tail vein or by oral gavage. Serial plasma samples were obtained, processed to isolate irinotecan and SN-38 lactone, and assayed with a sensitive and specific high-performance liquid chromatography assay. Noncompartmental and compartmental pharmacokinetic analyses were performed. A four-compartment model was used for analysis of irinotecan and SN-38 concentration-time data after i.v. administration. The presence of tumor increased irinotecan systemic exposure (1.2-3.8-fold; P < 0.05) after i.v. and oral administration in mice bearing neuroblastoma xenografts compared to non-tumor-bearing mice. Moreover, SN-38 systemic exposures were higher (1.3-3.8-fold; P < 0.05) in mice bearing human neuroblastoma xenografts as compared to non-tumor-bearing mice, with the greatest effect observed after oral administration of irinotecan. A schematic model is presented to provide a mechanistic basis for our observations. These results emphasize the need to perform preclinical pharmacokinetic studies to evaluate the influence of tumor on drug disposition.

This article has been cited by other articles:

				C. F. Stewart, M. Leggas, J. D. Schuetz, J. C. Panetta, P. J. Cheshire, J. Peterson, N. Daw, J. J. Jenkins III, R. Gilbertson, G. S. Germain, et al. Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice Cancer Res., October 15, 2004; 64(20): 7491 - 7499. [Abstract] [Full Text] [PDF]

				H. Stubdal, N. Perin, M. Lemmon, P. Holman, M. Bauzon, P. M. Potter, M. K. Danks, A. Fattaey, T. Dubensky, and L. Johnson A Prodrug Strategy Using ONYX-015-Based Replicating Adenoviruses to Deliver Rabbit Carboxylesterase to Tumor Cells for Conversion of CPT-11 to SN-38 Cancer Res., October 15, 2003; 63(20): 6900 - 6908. [Abstract] [Full Text] [PDF]

				H. M. Dodds, P. J. Tobin, C. F. Stewart, P. Cheshire, S. Hanna, P. Houghton, and L. P. Rivory The Importance of Tumor Glucuronidase in the Activation of Irinotecan in a Mouse Xenograft Model J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 649 - 655. [Abstract] [Full Text] [PDF]

				F. R. Luo, P. V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos., July 1, 2002; 30(7): 763 - 770. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) Clin. Cancer Res., August 1, 2001; 7(8): 2182 - 2194. [Abstract] [Full Text] [PDF]

				D. F. S. Kehrer, W. Yamamoto, J. Verweij, M. J. A. de Jonge, P. de Bruijn, and A. Sparreboom Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies Clin. Cancer Res., September 1, 2000; 6(9): 3451 - 3458. [Abstract] [Full Text]

				C. L. Morton, M. Wierdl, L. Oliver, M. K. Ma, M. K. Danks, C. F. Stewart, J. L. Eiseman, and P. M. Potter Activation of CPT-11 in Mice: Identification and Analysis of a Highly Effective Plasma Esterase Cancer Res., August 1, 2000; 60(15): 4206 - 4210. [Abstract] [Full Text]

				M. J. A. de Jonge, J. Verweij, P. de Bruijn, E. Brouwer, R. H. J. Mathijssen, R. J. van Alphen, M. M. de Boer-Dennert, L. Vernillet, C. Jacques, and A. Sparreboom Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin J. Clin. Oncol., January 5, 2000; 18(1): 195 - 195. [Abstract] [Full Text] [PDF]

				W. L. Furman, C. F. Stewart, C. A. Poquette, C. B. Pratt, V. M. Santana, W. C. Zamboni, L. C. Bowman, M. K. Ma, F. A. Hoffer, W. H. Meyer, et al. Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children J. Clin. Oncol., June 1, 1999; 17(6): 1815 - 1815. [Abstract] [Full Text] [PDF]